Delving into the Latest Updates on GO306(GeneSail Biotech) with Synapse

Overview

Basic Info

Drug Type

Oncolytic virus

Synonyms-

Target-

Action-

Mechanism-

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Advanced Malignant Solid NeoplasmColorectal CancerMalignant ascites+ [8]

Inactive Indication-

Originator Organization

GeneSail Biotech (Shanghai) Co., Ltd.

Active Organization

GeneSail Biotech (Shanghai) Co., Ltd.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

本研究分两个阶段：第一阶段评估 GO306 在标准治疗失败的晚期实体瘤患者中不同剂量水平下，单次肿瘤内注射/腔内给药的安全性、耐受性及初步有效性探索，并探索最大耐受剂量（MTD），确定第二阶段推荐剂量（RP2D）；第二阶段评估 GO306 在特定瘤种的患者中多次肿瘤内注射/腔内给药的安全性、耐受性及初步有效性探索，并确定最佳给药方案。

[Translation]

This study is divided into two phases: the first phase evaluates the safety, tolerability and preliminary efficacy of a single intratumoral injection/intracavitary administration of GO306 at different dose levels in patients with advanced solid tumors who have failed standard treatment, and explores the maximum tolerated dose (MTD) and determines the recommended dose for the second phase (RP2D); the second phase evaluates the safety, tolerability and preliminary efficacy of multiple intratumoral injections/intracavitary administration of GO306 in patients with specific tumor types, and determines the optimal dosing regimen.

Start Date-

Sponsor / Collaborator

GeneSail Biotech (Shanghai) Co., Ltd.

100 Clinical Results associated with GO306(GeneSail Biotech)

Login to view more data

100 Translational Medicine associated with GO306(GeneSail Biotech)

Login to view more data

100 Patents (Medical) associated with GO306(GeneSail Biotech)

Login to view more data

100 Deals associated with GO306(GeneSail Biotech)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Malignant Solid Neoplasm	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Colorectal Cancer	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Malignant ascites	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Microsatellite instability-high colorectal cancer	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Neuroendocrine Carcinoma	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Ovarian Epithelial Carcinoma	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Recurrent ovarian cancer	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Renal Cell Carcinoma	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Soft Tissue Sarcoma	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025
Triple Negative Breast Cancer	Phase 1	China	GeneSail Biotech (Shanghai) Co., Ltd.	16 May 2025